Multicenter Study on Incubation Conditions for Environmental Monitoring and Aseptic Process Simulation

References

1. 1.↵
   Eudralex Volume 4, EU GMP Annex 1. Manufacture of Sterile Medicinal Products, November 2008.
2. 2.↵
   2.6.1. Sterility. In European Pharmacopoeia; Council of Europe: Strasbourg, France.
3. 3.↵
   PI 007-05, Recommendation on the validation of aseptic processes, PIC/S, July 2009.
4. 4.↵
   U.S. Food and Drug Administration. Guide on Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice. Guidance for Industry, September 2004.
5. 5.↵
   PDA Technical Report 22. Process Simulations for Aseptically Filled Products; Parenteral Drug Association: Bethesda, MD, 2011.
6. 6.↵
   USP 35 <1116> Microbiological Control and Monitoring of Aseptic Processing Environments.
7. 7.↵
   USP 34 <1116> Microbiological Evaluation of Clean Rooms and Other Controlled Environments.
8. 8.↵
   World Health Organization. Environmental Monitoring of Clean Rooms in Vaccine Manufacturing Facilities, November 2012.
9. 9.↵
   1. Guinet R.

   Les Contrôles Environnementaux Suite aux Rencontres de Microbiologie. La Vague 2012, 35 (September), 17–19.

   OpenUrl
10. 10.↵
    1. Horn J.,
    2. Backes M.,
    3. Schepp E.-C.,
    4. P. Wenz P.

    Optimal Growth Conditions for Isolating Environmental Fungi from Air. 105th ASM Meeting, Atlanta, GA, June 5–9, 2005.
11. 11.↵
    Pharmaceutical and Healthcare Sciences Society (PHSS). Technical Monograph 20. Bio-contamination, September 2014.
12. 12.↵
    PDA Technical Report No. 13. Fundamentals of an Environmental Monitoring Program; Parenteral Drug Association: Bethesda, MD, 2014.
13. 13.↵
    1. Symonds I.,
    2. Martin D.,
    3. Davies M.

    Facility-Based Case Study: A Comparison of the Recovery of Naturally Occuring Species of Bacteria and Fungi on Semi-Solid Media When Incubated under Standard and Dual Temperature Conditions and Its Impact on Environmental Monitoring Approach. Eur. J. Par. Pharm. Sci. 2016, 21 (1), 7–15.

    OpenUrl
14. 14.↵
    1. Gordon O.,
    2. Berchtold M.,
    3. Staerk A.,
    4. Roesti D.

    Comparison of Different Incubation Conditions for Microbiological Environmental Monitoring. PDA J. Pharm. Sci. Technol. 2014, 68 (5), 394–406.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Guinet R.

    Propositions de Modifications Spécifiques de l'Annexe 1. La Vague 2015, 47 (September), 27–32.

    OpenUrl
16. 16.↵
    1. Guinet R.

    , Résultats du Vote sur les Propositions du GIC A3P de Modifications Envisageables de l'Annexe 1. La Vague 2015, 44 (January), 7–8.

    OpenUrl
17. 17.↵
    1. Marshall V.,
    2. Poulson-Cook S.,
    3. Moldenhauer J.

    Comparative Mold and Yeast Recovery Analysis (The Effect of Differing Incubation Temperature Ranges and Growth Media). PDA J. Pharm. Sci. Technol. 1998, 52 (4), 165–169.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Gebala B.,
    2. Sandle T.

    Comparison of Different Fungal Agar for the Environmental Monitoring of Pharmaceutical-Grade Cleanrooms. PDA J. Pharm. Sci. Technol. 2013, 67 (6), 621–633.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    1. Weissfeld A. S.,
    2. Joseph R. A.,
    3. Le T. V.,
    4. Trevino E. A.,
    5. Schaeffer M. F.,
    6. Vance P. H.

    Optimal Media for Use in Air Sampling To Detect Cultivable Bacteria and Fungi in the Pharmacy. J. Clin. Microbiol. 2013, 51 (10), 3172–3175.

    OpenUrlAbstract/FREE Full Text